Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines

Journal of Orthopaedic Research

Volumn 29, Issue 11, 2011, Pages 1707-1711

  Fujimori, Jun ^a   Matsuo, Toshihiro ^a   Shimose, Shoji ^a   Kubo, Tadahiko ^a   Ishikawa, Masakazu ^a   Yasunaga, Yuji ^a   Ochi, Mitsuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

cationic porphyrin; osteosarcoma; telomerase; telomere; TMPyP4

Indexed keywords

5,10,15,20 TETRA (N METHYL 4 PYRIDYL)PORPHYRIN; ANTINEOPLASTIC AGENT; PORPHYRIN DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TELOMERE;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; OSTEOSARCOMA; PORPHYRINS; TELOMERASE; TELOMERE;

EID: 80053193616     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21451     Document Type: Article

References (40)

1. Zakian VA,. 1989. Structure and function of telomeres. Annu Rev Genet 23: 579-604. (Pubitemid 20033416)
2. Blackburn EH,. 1992. Telomerases. Annu Rev Biochem 61: 113-129.
3. Greider CW, Blackburn EH,. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413. (Pubitemid 16213265)
4. Lingner J, Cech TR,. 1998. Telomerase and chromosome end maintenance. Curr Opin Genet Dev 8: 226-232. (Pubitemid 28206287)
5. Kim NW, Piatyszek MA, Prowse KR, et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
6. de Lange T,. 1994. Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 91: 2882-2885. (Pubitemid 24130136)
7. Bryan TM, Englezou A, Dalla-Pozza L, et al. 1997. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271-1274. (Pubitemid 27508830)
8. Bryan TM, Reddel RR,. 1997. Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur J Cancer 33: 767-773.
9. Henson JD, Hannay JA, McCarthy SW, et al. 2005. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11: 217-225. (Pubitemid 40075798)
10. Ulaner GA, Hoffman AR, Otero J, et al. 2004. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41: 155-162. (Pubitemid 39096741)
11. Costa A, Daidone MG, Daprai L, et al. 2006. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66: 8918-8924. (Pubitemid 44449211)
12. Matsuo T, Shay JW, Wright WE, et al. 2009. Telomere-maintenance mechanisms in soft tissue malignant fibrous histiocytomas. J Bone Joint Surg Am 91: 928-937.
13. Izbicka E, Wheelhouse RT, Raymond E, et al. 1999. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 59: 639-644. (Pubitemid 29076062)
14. Grand CL, Han H, Muñoz RM, et al. 2002. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 1: 565-573.
15. Kim MY, Gleason-Guzman M, Izbicka E, et al. 2003. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res 63: 3247-3256. (Pubitemid 36735879)
16. Scheel C, Schaefer KL, Jauch A, et al. 2001. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20: 3835-3844. (Pubitemid 32646194)
17. Vera E, Canela A, Fraga MF, et al. 2008. Epigenetic regulation of telomeres in human cancer. Oncogene 27: 6817-6833.
18. Hiyama E, Hiyama K,. 2002. Clinical utility of telomerase in cancer. Oncogene 21: 643-649. (Pubitemid 34146266)
19. Shay JW,. 1998. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. Cancer J Sci Am 4: 26-34.
20. Hiyama E, Hiyama K, Yokoyama T, et al. 1995. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1: 249-255.
21. Hiyama E, Yokoyama T, Tatsumoto N, et al. 1995. Telomerase activity in gastric cancer. Cancer Res 55: 3258-3262.
22. Wright WE, Piatyszek MA, Rainey WE, et al. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18: 173-179. (Pubitemid 26116862)
23. Kim MM, Rivera MA, Botchkina IL, et al. 2001. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA 98: 7982-7987. (Pubitemid 32642673)
24. Neidle S, Parkinson G,. 2002. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov 1: 383-393. (Pubitemid 37361468)
25. Shay JW, Wright WE,. 2002. Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-265. (Pubitemid 41043959)
26. Jackson SR, Zhu CH, Paulson V, et al. 2007. Antiadhesive effects of GRN163L-an oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase. Cancer Res 67: 1121-1129.
27. Parkhurst MR, Riley JP, Igarashi T, et al. 2004. Immunization of patients with the hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10: 4688-4698. (Pubitemid 38955519)
28. Su Z, Dannull J, Yang BK, et al. 2005. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174: 3798-3807. (Pubitemid 40354093)
29. Brunsvig PF, Aamdal S, Gjertsen MK, et al. 2006. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55: 1553-1564. (Pubitemid 44327843)
30. Domchek SM, Recio A, Mick R, et al. 2007. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 67: 10546-10555. (Pubitemid 350070831)
31. Bolonaki I, Kotsakis A, Papadimitraki E, et al. 2007. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25: 2727-2734. (Pubitemid 47123180)
32. Shay JW, Wright WE,. 2005. Telomerase and human cancer. In:, de Lange T, Lundblad V, Blackburn E, editors. Telomeres, 2nd ed. New York: Cold Spring Harbor Laboratory Press; p 81-108.
33. Rhodes D, Giraldo R,. 1995. Telomere structure and function. Curr Opin Struct Biol 5: 311-322.
34. Lipps HJ, Rhodes D,. 2009. G-quadruplex structures: in vivo evidence and function. Trends Cell Biol 19: 414-422.
35. Zahler AM, Williamson JR, Cech TR, et al. 1991. Inhibition of telomerase by G-quartet DNA structures. Nature 350: 718-720. (Pubitemid 21912306)
36. Hurley LH, Wheelhouse RT, Sun D, et al. 2000. G-quadruplexes as targets for drug design. Pharmacol Ther 85: 141-158. (Pubitemid 30160784)
37. Harley CB, Futcher AB, Greider CW,. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460.
38. Rosen G, Marcove RC, Caparros B, et al. 1979. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163-2177. (Pubitemid 9246383)
39. Ham SJ, Schraffordt Koops H, van der Graaf WT, et al. 1998. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol 24: 584-600. (Pubitemid 28566909)
40. Matsuo T, Shimose S, Kubo T, et al. 2009. Telomeres and telomerase in sarcomas. Anticancer Res 29: 3833-3836.